ITOS VS ERAS Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

ERAS
10/100

ERAS returned -71.18% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

ERAS

"Sentiment" not found for ERAS

Technicals

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

ERAS
64/100

ERAS receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

ERAS
100/100

ERAS has missed earnings 1 times in the last 20 quarters.

Profit

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

ERAS
10/100

Out of the last 15 quarters, ERAS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

ERAS
46/100

ERAS has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

All score calculations are broken down here to help you make more informed investing decisions

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS
Healthcare
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Erasca, Inc. Common Stock Summary

Nasdaq / ERAS
Healthcare
Biotechnology
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.